Intellia Therapeutics, Inc. (NTLA)
Automate Your Wheel Strategy on NTLA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTLA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTLA
- Rev/Share 0.4403
- Book/Share 7.5354
- PB 1.6137
- Debt/Equity 0.1529
- CurrentRatio 4.8972
- ROIC -0.5931
- MktCap 1259569280.0
- FreeCF/Share -3.6827
- PFCF -3.3046
- PE -2.3931
- Debt/Assets 0.1209
- DivYield 0
- ROE -0.5867
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NTLA | Wolfe Research | Peer Perform | Outperform | -- | $21 | April 21, 2025 |
| Initiation | NTLA | H.C. Wainwright | -- | Buy | -- | $30 | March 5, 2025 |
| Downgrade | NTLA | Goldman | Neutral | Sell | -- | $9 | Feb. 28, 2025 |
| Downgrade | NTLA | JP Morgan | Overweight | Neutral | $45 | $13 | Feb. 28, 2025 |
| Downgrade | NTLA | Morgan Stanley | Overweight | Equal Weight | $56 | $11 | Jan. 27, 2025 |
News
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Intellia Therapeutics, Inc.
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.
Read More
Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 422.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NTLA
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129471&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025.
Read More
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129429&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. (NTLA) Shareholders
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129390&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) and certain of its officers.
Read More
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.
Read More
NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129319&wire=1 or contact Joseph E. Levi, Esq.
Read More
Intellia Therapeutics, Inc. Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.
Read More
NTLA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129170&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Feb. 13, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ: NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.
Read More
Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129145&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investor Alert: Robbins LLP Informs Stockholders of the Intellia Therapeutics, Inc. Class Action
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 12, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, Inc. (NASDAQ: NTLA) securities between June 30, 2024 and January 28, 2025. Intellia describes itself as a leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129114&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Intellia Therapeutics, Inc.
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.
Read More
Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 – NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129099&wire=1 or contact Joseph E. Levi, Esq.
Read More
Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129089&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA). The lawsuit alleges that Defendants made material misrepresentations concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease.
Read More
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129078&wire=1 or contact Joseph E. Levi, Esq.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. (NTLA)
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased the securities of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”).
Read More
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129061&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Intellia Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2025
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) between July 30, 2024 to January 8, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Marcos Gonzalez v.
Read More
About Intellia Therapeutics, Inc. (NTLA)
- IPO Date 2016-05-06
- Website https://www.intelliatx.com
- Industry Biotechnology
- CEO John M. Leonard
- Employees 403